Search ARM

Ovizio Imaging Systems, founded in 2009, develops and commercializes a quantitative microscopic imaging platform technology based on patented Differential Digital Holographic Microscopy (DDHM). Ovizio is establishing its footprint in the Bioprocessing market, with a focus on Cell and Gene Therapy and Vaccine production. Other than their imaging platform, Ovizio’s product line includes the BioConnect, which is a single-use disposable and autoclavable closed loop fluidics system. It is specifically designed with a cell-friendly membrane pump working like a heart. Thanks to an automatic and continuously flushing, cells flow through the imaging device and flow back to the bioreactor after holograms of the cells have been captured.

Ovizio recently announced the execution of supply agreements with Celgene Corporation for the automation of certain engineered T cell manufacturing processes. Celgene will be using Ovizio’s innovative on-line iLine F microscope, and the BioConnect system, a closed, single-use fluidic sampling system, to further automate the manufacturing of engineered T-cell investigational products and improve product control across their global manufacturing network. These agreements follow a technology development cooperative effort initiated in 2018. Emilie Viey, CEO of Ovizio Imaging Systems: “We are proud to support Celgene’s efforts in cell therapy, developing innovative programs for patients in areas of high unmet need. As a supportive technology partner, we are excited for the opportunities ahead as we continue our work with Celgene, seamlessly integrating Ovizio’s innovative microscopy solution into their engineered T-cell products manufacturing process.”

Contact Ovizio Imaging Systems